With recent interest in immunotherapy on the rise, researchers led by Mirona Attrash treated an older patient presenting with invasive conjunctival melanoma who elected to bypass surgery with the combination of relatlimab-nivolumab (anti-PD-L1/anti-LAG3 inhibitors).
Clinical Trials
First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo – promising use of Lytix cancer treatment in patients with early-stage melanoma
Oslo, Norway, November 6, 2024 – Lytix Biopharma, a Norwegian immuno-oncology company dedicated to being part of tomorrow’s cancer treatment, announces that the first patient has been treated in a new Phase II trial (NeoLIPA). The study evaluates the effect of Lytix’s lead drug candidate, LTX-315, in early-stage patients diagnosed with melanoma. Melanoma is the most severe type of skin cancer with a rising incidence globally and an estimated global market of USD 11 billion by 2030.
Retrospective Analysis Across Six CheckMate Trials Reinforces Benefit of Nivolumab Plus Ipilimumab
A pooled analysis of six CheckMate studies in immune checkpoint inhibitor (ICI), specifically treatment with nivolumab plus ipilimumab (NIVO + IPI) versus NIVO monotherapy, aimed to describe the long-term overall survival in patients with ICI treatment-naïve unresectable/metastatic melanoma.
Vidutolimod Plus Nivolumab Proves Active in High-Risk, Resectable Melanoma
The combination of vidutolimod and nivolumab demonstrated activity in a phase 2 trial of patients with high-risk, resectable melanoma, according to researchers. They reported these findings in Cancer Cell.